CoChat

A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises

Open access

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Abstract

Background: The US Food and Drug Administration’s accelerated approval and later withdrawal of bevacizumab in patients with metastatic breast cancer (mBC) is a seminal case for ongoing debates about the validity of using progression-free survival (PFS) as a surrogate measure for overall survival (OS) in cancer drug approvals. We systematically reviewed and meta-analyzed the evidence around bevacizumab’s regulatory approval and withdrawal in mBC. Methods: We searched for all published phase II or III clinical trials testing bevacizumab as a first-line therapy for patients with mBC. Data were extracted on trial demographics, interventions, and outcomes. Descriptive analysis was stratified by whether the trial was initiated before, during, or after the accelerated approval. We used a cumulative random-effects meta-analysis to assess the evolution of evidence of the effect of bevacizumab on PFS and OS. We estimated the association between the trial-level PFS and OS effect using a nonlinear mixed-regression model. Results: Fifty-two studies were included. Trial activity dramatically dropped after the accelerated approval was withdrawn. Eight clinical trials reported hazard ratios (hazard ratios) and were meta-analyzed. The cumulative hazard ratio for PFS was 0.72 (95% CI = 0.65 to 0.79), and the cumulative hazard ratio for OS was 0.90 (95% CI = 0.80 to 1.01). The regression model showed a statistically nonsignificant association between PFS benefit and OS benefit (β = 0.43, SE = 0.81). Conclusion: The US Food and Drug Administration’s decision-making in this case was consistent with the evolving state of evidence. However, the fact that seven clinical trials are insufficient to conclude validity (or lack thereof) for a trial-level surrogate suggests that it would be more efficient to conduct trials using the more clinically meaningful endpoints.

Overview

Integrity signals

Registry

Crossref · 10.1093/jnci/djz211

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. Pazdur, 2010, Regulatory Decision to Withdraw Avastin (Bevacizumab) First-Line Metastatic Breast Cancer Indication

Cited by

See all 31

Metadata

Authors
Hey, S. P., Gyawali, B., D’Andrea, E., Kanagaraj, M., Franklin, J. M., & Kesselheim, A. S.
Affiliations
  • Brigham and Women's Hospital (US)
  • Harvard University (US)
Corresponding author
Hey, Spencer Phillips
Venue
JNCI: Journal of the National Cancer Institute
Published
2019-10-25
Volume
112
Issue
4
Pages
335-342
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2982249510
Cited by
29
References
42
Citations by year
2026: 2 · 2025: 7 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 3
FWCI
0.34
Type
journal article
Language
en
Open access
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Arnold Ventures
  • Harvard-MIT Center for Regulatory Science
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
bevacizumab, metastatic breast cancer, first-line therapy, accelerated approval, surrogate endpoints, progression-free survival, overall survival, FDA regulatory decision-making
MeSH terms
Bevacizumab, Antineoplastic Agents, Immunological, Progression-Free Survival, Breast Neoplasms, Decision Making, Female, Humans, Legislation, Drug, Neoplasm Metastasis, Regression Analysis, United States, United States Food and Drug Administration, Survival Rate, Randomized Controlled Trials as Topic, Drug Approval, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Nonlinear Dynamics, Endpoint Determination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. https://app.cochat.ai/papers/10.1093/jnci/djz211
The paper
Hey, S. P., Gyawali, B., D’Andrea, E., Kanagaraj, M., Franklin, J. M., & Kesselheim, A. S. (2020). A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djz211

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.